11 results on '"Yin, Yongmei"'
Search Results
2. Relationship between tRNA‐derived fragments and human cancers.
- Author
-
Zeng, Tianyu, Hua, Yijia, Sun, Chunxiao, Zhang, Yuchen, Yang, Fan, Yang, Mengzhu, Yang, Yiqi, Li, Jun, Huang, Xiang, Wu, Hao, Fu, Ziyi, Li, Wei, and Yin, Yongmei
- Subjects
CANCER cell proliferation ,NON-coding RNA ,TRANSFER RNA ,CANCER ,GENE expression - Abstract
tRNA‐derived fragments, a class of small noncoding RNAs (sncRNAs), have been identified in numerous studies in recent years. tRNA‐derived fragments are classified into two main groups, including tRNA halves (tiRNAs) and tRNA‐derived small RNA fragments (tRFs), according to different cleavage positions of the precursor or mature tRNAs. Instead of random tRNA degradation debris, a growing body of evidence has shown that tRNA‐derived fragments are precise products of specific tRNA modifications and play important roles in biological activities, such as regulating protein translation, affecting gene expression, and altering immune signaling. Recently, the relations between tRNA‐derived fragments and the occurrence of human diseases, especially cancers, have generated wide interest. It has been demonstrated that tRNA‐derived fragments are involved in cancer cell proliferation, metastasis, progression and survival. In this review, we will describe the biogenesis of tRNA‐derived fragments, the distinct expression and function of tRNA‐derived fragments in the development of cancers, and their emerging roles as diagnostic and prognostic biomarkers and precise targets of future treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. tRNA-Derived Fragments as Novel Predictive Biomarkers for Trastuzumab-Resistant Breast Cancer.
- Author
-
Sun, Chunxiao, Yang, Fan, Zhang, Yanhong, Chu, Jiahui, Wang, Jian, Wang, Yifan, Zhang, Yanqiu, Li, Jun, Li, Yongfei, Fan, Ruihua, Li, Wei, Huang, Xiang, Wu, Hao, Fu, Ziyi, Jiang, Zefei, and Yin, Yongmei
- Subjects
MICRORNA ,BREAST cancer ,BIOMARKERS ,TRASTUZUMAB ,CANCER treatment - Abstract
Background/Aims: Resistance to trastuzumab remains a common challenge to HER-2 positive breast cancer. Up until now, the underlying mechanism of trastuzumab resistance is still unclear. tRNA-derived small non-coding RNAs, a new class of small non-coding RNA (sncRNAs), have been observed to play an important role in cancer progression. However, the relationship between tRNA-derived fragments and trastuzumab resistance is still unknown.Methods: We detected the levels of tRNA-derived fragments expression in normal breast epithelial cell lines, trastuzumab-sensitive and -resistant breast cancer cell lines using high-throughput sequencing. qRT-PCR was conducted to validate the differentially expressed fragments in serums from trastuzumab-sensitive and -resistant patients. A receiver operating characteristic (ROC) curve analysis was performed to evaluate the power of specific tRNA-derived fragments. Progression-free survival (PFS) was analyzed using Cox-regression.Results: Our sequence results showed that tRNA-derived fragments were differentially expressed in the HBL-100, SKBR3, and JIMT-1 cell lines. tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN were found significantly upregulated in trastuzumab-resistant patients compared to sensitive individuals, and the ROC analysis showed that tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN were correlated with trastuzumab resistance. In a multivariate analysis, higher levels of tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN expression were associated with significantly shorter PFS in patients with metastatic HER-2 positive breast cancer.Conclusion: Our results suggest that tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN play important roles in trastuzumab resistance. Patients with high levels of tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN expression benefitted less from trastuzumab-based therapy than those that express lower-levels of these molecules. tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN may be potential biomarkers and intervention targets in the clinical treatment of trastuzumab-resistant breast cancer. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
4. Icotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective Study.
- Author
-
Chen, Xiaofeng, Zhu, Quan, Liu, Yiqian, Liu, Ping, Yin, Yongmei, Guo, Renhua, Lu, Kaihua, Gu, Yanhong, Liu, Lianke, Wang, Jinghua, Wang, Zhaoxia, Røe, Oluf Dimitri, Shu, Yongqian, and Zhu, Lingjun
- Subjects
LUNG cancer treatment ,CROWN ethers ,EPIDERMAL growth factor receptors ,PROTEIN-tyrosine kinase inhibitors ,DISEASE progression ,RETROSPECTIVE studies - Abstract
Background: Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with preclinical and clinical activity in non-small cell lung cancer (NSCLC). This retrospective analysis was performed to assess the efficacy of icotinib on patients with non-small-cell lung cancer (NSCLC). Methods: 82 consecutive patients treated with icotinib as first (n = 24) or second/third line (n = 58) treatment at three hospitals in Nanjing were enrolled into our retrospective research. The Response Evaluation Criteria in Solid Tumors (RECIST) was used to evaluate the tumor responses and the progression-free survival (PFS) and overall survival (OS) was evaluated by the Kaplan-Meier method. Results: Median PFS was 4.0 months (95% CI 2.311–5.689). Median OS was 11.0 months (95% CI 8.537–13.463) in this cohort. Median PFS for first and second/third line were 7.0 months (95% CI 2.151–11.8) and 3.0 months (95% CI 1.042–4.958), respectively. Median OS for first and second/third line were 13.0 months (95% CI 10.305–15.695) and 10.0 months (95% CI 7.295–12.70), respectively. In patients with EGFR mutation (n = 19), icotinib significantly reduced the risk of progression (HR 0.36, 95% CI 0.18–0.70, p = 0.003) and death (HR 0.10, 95% CI 0.02–0.42, p = 0.002) compared with those EGFR status unknown (n = 63). The most common adverse events were acne-like rash (39.0%) and diarrhea (20.7%). Conclusions: Icotinib is active in the treatment of patients with NSCLC both in first or second/third line, especially in those patients harbouring EGFR mutations, with an acceptable adverse event profile. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
5. Genetic Variations in the Flanking Regions of miR-101-2 Are Associated with Increased Risk of Breast Cancer.
- Author
-
Chen, Jiaping, Qin, Zhenzhen, Jiang, Yue, Wang, Yanru, He, Yisha, Dai, Juncheng, Jin, Guangfu, Ma, Hongxia, Hu, Zhibin, Yin, Yongmei, and Shen, Hongbing
- Subjects
HUMAN genetic variation ,BREAST cancer risk factors ,MICRORNA ,DISEASE susceptibility ,DISEASE progression ,CANCER treatment ,CANCER cells - Abstract
Genetic variants in human microRNA (miRNA) genes may alter mature miRNA processing and/or target selection, and likely contribute to cancer susceptibility and disease progression. Previous studies have suggested that miR-101 may play important roles in the development of cancer by regulating key tumor-associated genes. However, the role of single nucleotide polymorphisms (SNPs) of miR-101 in breast cancer susceptibility remains unclear. In this study, we genotyped 11 SNPs of the miR-101 genes (including miR-101-1 and miR-101-2) in a case-control study of 1064 breast cancer cases and 1073 cancer-free controls. The results revealed that rs462480 and rs1053872 in the flank regions of pre-miR-101-2 were significantly associated with increased risk of breast cancer (rs462480 AC/CC vs AA: adjusted OR = 1.182, 95% CI: 1.030–1.357, P = 0.017; rs1053872 CG/GG vs CC: adjusted OR = 1.179, 95% CI: 1.040–1.337, P = 0.010). However, the remaining 9 SNPs were not significantly associated with risk of breast cancer. Additionally, combined analysis of the two high-risk SNPs revealed that subjects carrying the variant genotypes of rs462480 and rs1053872 had increased risk of breast cancer in a dose-response manner (P
trend = 0.002). Compared with individuals with “0–1” risk allele, those carrying “2–4” risk alleles had 1.29-fold risk of breast cancer. In conclusion, these findings suggested that the SNPs rs462480 and rs1053872 residing in miR-101-2 gene may have a solid impact on genetic susceptibility to breast cancer, which may improve our understanding of the potential contribution of miRNA SNPs to cancer pathogenesis. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
6. Gefitinib or Erlotinib as Maintenance Therapy in Patients with Advanced Stage Non-Small Cell Lung Cancer: A Systematic Review.
- Author
-
Chen, Xiaofeng, Liu, Yiqian, Røe, Oluf Dimitri, Qian, Yingying, Guo, Renhua, Zhu, Lingjun, Yin, Yongmei, and Shu, Yongqian
- Subjects
LUNG cancer treatment ,CANCER chemotherapy ,GEFITINIB ,EPIDERMAL growth factor receptors ,PROTEIN-tyrosine kinases ,KINASE inhibitors ,DRUG administration ,SYSTEMATIC reviews ,MEDICAL databases - Abstract
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC). The studies are quite heterogenous regarding study size and populations, and a synopsis of these data could give some more insight in the role of maintenance therapy with TKI. Methods: In September 2012 we performed a search in the pubmed, EMBASE and Cochrane library databases for randomized phase III trials exploring the role of gefitinib or erlotinib in advanced non-small cell lung cancer. Through a rigorous selection process with specific criteria, five trials (n = 2436 patients) were included for analysis. Standard statistical methods for meta-analysis were applied. Results: TKIs (gefitinib and erlotinib) significantly increased progression-free survival (PFS) [hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.50–0.76, I
2 = 78.1%] and overall survival (HR 0.84, 95% CI 0.76–0.93, I2 = 0.0%) compared with placebo or observation. The PFS benefit was consistent in all subgroups including stage, sex, ethnicity, performance status, smoking status, histology, EGFR mutation status, and previous response to chemotherapy. Patients with clinical features such as female, never smoker, adenocarcinoma, Asian ethnicity and EGFR mutation positive had more pronounced PFS benefit. Overall survival benefit was observed in patients with clinical features such as female, non-smoker, smoker, adenocarcinoma, and previous stable to induction chemotherapy. Severe adverse events were not frequent. Main limitations of this analysis are that it is not based on individual patient data, and not all studies provided detailed subgroups analysis. Conclusions: The results show that maintenance therapy with erlotinib or gefitinib produces a significant PFS and OS benefit for unselected patients with advanced NSCLC compared with placebo or observation. Given the less toxicity of TKIs than chemotherapy and simple oral administration, this treatment strategy seems to be of important clinical value. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
7. Micro RNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor.
- Author
-
Liu, Lingxiang, Shao, Xiaoyan, Gao, Wen, Zhang, Zhi, Liu, Ping, Wang, Rongsheng, Huang, Puwen, Yin, Yongmei, and Shu, Yongqian
- Subjects
SMALL cell lung cancer ,CANCER treatment ,MICRORNA ,EPIDERMAL growth factor receptors ,GENE expression ,APOPTOSIS ,GENE targeting ,CELLULAR signal transduction ,CANCER cell growth ,ENZYME inhibitors - Abstract
Both the deregulation of microRNAs and epidermal growth factor receptor ( EGFR) are emerging as important factors in non-small-cell lung cancer ( NSCLC). Here, miR-133b was found to be associated with tumor stage, the extent of regional lymph node involvement, stage, visceral pleura or vessel invasion and EGFR mRNA expression in Chinese patients with NSCLC. Bioinformatic analysis and luciferase reporter assay revealed that miR-133b can interact specifically with the 3′- UTR of EGFR mRNA. Functionally, miR-133b transfection showed regulatory activity in translationally repressing EGFR mRNA. Moreover, miR-133b transfection may modulate apoptosis, invasion and sensitivity to EGFR-TKI through the EGFR signaling pathways, especially in EGFR-addicted NSCLC cells. Taken together, our findings show that miR-133b can inhibit cell growth of NSCLC through targeting EGFR and regulating its downstream signaling pathway. This finding has important implications for the development of targeted therapeutics for a number of EGFR-addicted cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
8. A case of intimal sarcoma of the pulmonary artery successfully treated with chemotherapy.
- Author
-
Xu, Yanjie, Wang, Kai, Geng, Yiting, Shao, Yongfeng, and Yin, Yongmei
- Subjects
PULMONARY artery diseases ,CANCER treatment ,SARCOMA ,CANCER chemotherapy ,TREATMENT effectiveness ,DISEASES in middle-aged women ,ENDARTERECTOMY ,CANCER tomography ,THERAPEUTICS - Abstract
Intimal sarcoma of pulmonary artery (PAIS) is a rare disease with no characteristic symptoms. No standard therapeutic guidelines have been established so far. A 55-year-old woman who underwent pulmonary endarterectomy in 2005 with a pathological and immunohistochemical result of PAIS was re-admitted to our hospital on August 24, 2009, presenting with cough and dyspnea. The thoracic computed tomography (CT) scan revealed a 12.5 cm × 9 cm well-defined mass in the right lobe, considered a local neoplasm recurrence after a 44 month symptom-free period. As surgical resection was not proposed, she received combined chemotherapy consisting of doxorubicin, cisplatin, and ifosfamide for two cycles. Because of intolerable side effects, she received vinorelbine and cisplatin for the next four cycles. CT scans after six cycles showed remarkable regression of the tumor. After that, she began to take oral cyclophosphamide (50 mg t.i.d) everyday as a maintenance therapy. As of the time of writing, 19 months after the onset of the recurrence, she remains stable. Several antineoplastic drugs have been reported to be used in PAIS, with poor effects in most cases. To our knowledge, this is the first case of PAIS that has been successfully treated by a vinorelbine-based regimen used as second-line chemotherapy. Vinorelbine is a promising drug that may be relatively well tolerated in heavily pretreated patients with PAIS. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
9. Improved cancer phototheranostic efficacy of hydrophobic IR780 via parenteral route by association with tetrahedral nanostructured DNA.
- Author
-
Wang, Shuo, Liu, Zengyi, Tong, Yue, Zhai, Yunqian, Zhao, Xiujie, Yue, Xinmin, Qiao, Yanqi, Liu, Yonghui, Yin, Yongmei, Xi, Rimo, Zhao, Wei, and Meng, Meng
- Subjects
- *
DNA , *INTRAVENOUS injections , *INTRAVENOUS therapy , *ELECTROSTATIC interaction , *CANCER treatment , *INFRARED imaging - Abstract
As a photosensitizer with effective photothermal (PTT) and photodynamic (PDT) response, IR780 has been widely explored as promising cancer phototheranostic molecule. However, the systematic administration of IR780 usually suffers from poor water solubility and low photostability, so that it cannot be administrated by parenteral route. In this study, we design a tetrahedral DNA (Td)-based nanosystem to load IR780 (IR780@Td) via electrostatic interaction and π-π stacking. After encapsulation, the water solubility and photostability of IR780 have been greatly improved, and the IR780@Td shows an appropriate nanoformulated size (224 nm) to facilitate hyperthermia-mediated tumor targeting by EPR effect. The nanostructure of Td is proved to be crucial for the proper size and good stability of IR780@Td nanoformulation for in vivo application. The in vitro and ex vivo PTT/PDT efficiencies of IR780 are improved in IR780@Td group. In the tumor-bearing mice, the accumulation of IR780 in tumor site is significantly high in IR780@Td group. Under near-infrared laser irradiation, the intravenous administration of IR780@Td promotes the tumor imaging and enhances anti-tumor effect than IR780 treatment. In summary, the proposed strategy shows promising effect in facilitating intravenous injection of IR780 and enhancing the phototheranostic efficacy for cancer treatment. Unlabelled Image • Atetrahedral DNA nanostructure (Td) was used toload hydrophobic IR780 (IR780@Td) by electrostatic binding. • The water solubility and photo stability of IR780 have been greatly improved. • The nanostructure of Td is proved important to obtain IR780 nanoparticles with EPR effect. • The PTT/PDT efficiency of IR780 are improved in IR780@Td group. • IR780@Td shows specific tumor imaging and enhanced anti-tumor effect. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. A novel method to assay molecular chaperone activity of HSP70: Evaluation of drug resistance in cancer treatment.
- Author
-
Ding, Xiaorong, Li, Hao, Xie, Haona, Huang, Yue, Hou, Yafei, Yin, Yongmei, and Li, Genxi
- Subjects
- *
MOLECULAR chaperones , *BIOLOGICAL assay , *HEAT shock proteins , *DRUG resistance , *CANCER treatment , *BIOCHEMICAL substrates - Abstract
Abstract: In this work, we have proposed a novel method to specifically assay the molecular chaperone activity of HSP70 based on the HSP70-substrate peptide interaction. By selectively labeling the substrate peptide of HSP70 via host–guest interaction with two different cucurbituril species, the HSP70-substrate peptide interaction can be transduced into detectable signal readout. By using the signal readout, assay of the molecular chaperone activity of HSP70 can be achieved. Moreover, by using our method, chaperone activity of HSP70 can serve as a reliable indicator of drug resistance in cancer treatment. The experimental results reveal that enhanced chaperone activity of HSP70 is observed in both drug-resistant cancer cell line and the serum of cancer victim subject to anti-cancer therapy. Therefore, the proposed method to assay the molecular chaperone activity of HSP70 can be a tool of efficiency in evaluating therapeutic response in HSP70-targeted cancer treatment. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
11. Effect of gefitinib challenge to initial treatment with non-small cell lung cancer
- Author
-
Chen, Xiaofeng, Li, Wei, Hu, Xiaoli, Geng, Yiting, Wang, Rong, Yin, Yongmei, and Shu, Yongqian
- Subjects
- *
CANCER treatment , *SMALL cell lung cancer , *CANCER patients , *CANCER invasiveness , *EPIDERMAL growth factor receptors , *HEPATOTOXICOLOGY , *GENETIC mutation , *DNA - Abstract
Abstract: Purposes: This study was conducted to assess the efficacy and toxicity of gefitinib as first line treatment in patients with advanced non-small-cell lung cancer (NSCLC). Methods: Tumor tissue, derived from either the original tumor or the metastatic or recurrent site was taken from chemo-naïve patients with advanced (stage IIIB, IV and recurrent) NSCLC. Tumor genomic DNA underwent direct sequencing for EGFR exons 18, 19, 20 and 21. Sixty-one patients received 250mg of gefitinib daily until disease progression or unacceptable toxicity. Results: Out of 61 patients, 26 patients (42.6%) were EGFR mutations and 11 patients were wild type, 24 patients were status unknown. One patient achieved complete remission (CR). While 17 patients achieved partial remission (PR) and 23 experienced stable disease (SD). There were 20 patients developed progressive disease (PD). The tumor response rate and disease control rate was 29.5 and 67.2%, respectively, and symptom remission rate was 66.7% as well. Median remission time was 9 days. Median over survival time was 13.0 months. Median progression-free survival time was 5.0 months. The MST of patients with EGFR mutation was 17.0 months, while the MST of patients with EGFR status unknown or wild type was 11.0 months. The PFS of patients with EGFR mutation was 9.0 months and it in EGFR status unknown or wild type was 2.5 months .The most common toxicity included rash (54.1%) and diarrhea (31.1%). Dehydration and pruritus of skin was observed in 31.1 and 26.2% of the patients respectively. Hepatic toxicity occurred in 8.2% of patients and oral ulceration occurred in six patients (9.8%). Conclusion: Single agent treatment with gefitinib is effective in patients with advanced NSCLC, especially in patients with EGFR mutation, and well tolerated in Chinese patients. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.